These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12393542)

  • 1. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
    Hideshima T; Akiyama M; Hayashi T; Richardson P; Schlossman R; Chauhan D; Anderson KC
    Blood; 2003 Jan; 101(2):703-5. PubMed ID: 12393542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
    Gupta D; Treon SP; Shima Y; Hideshima T; Podar K; Tai YT; Lin B; Lentzsch S; Davies FE; Chauhan D; Schlossman RL; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling DI; Anderson KC
    Leukemia; 2001 Dec; 15(12):1950-61. PubMed ID: 11753617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Akiyama M; Richardson P; Schlossman RL; Chauhan D; Munshi NC; Waxman S; Anderson KC
    Mol Cancer Ther; 2002 Aug; 1(10):851-60. PubMed ID: 12492118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Podar K; Catley LP; Tai YT; Shringarpure R; Carvalho P; Hayashi T; Burger R; Schlossman RL; Richardson PG; Pandite LN; Kumar R; Hideshima T; Chauhan D; Anderson KC
    Blood; 2004 May; 103(9):3474-9. PubMed ID: 14644994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
    Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
    Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma].
    Zhang L; Chen SL; Chen WM; Liu JW
    Zhonghua Nei Ke Za Zhi; 2005 Feb; 44(2):85-8. PubMed ID: 15840215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mitogen-activated protein kinase family in serum-induced leukaemia inhibitory factor and interleukin-6 secretion by bone marrow stromal cells.
    Nakao T; Kim S; Ohta K; Kawano H; Hino M; Miura K; Tatsumi N; Iwao H
    Br J Pharmacol; 2002 Aug; 136(7):975-84. PubMed ID: 12145097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
    Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
    Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
    Gupta D; Podar K; Tai YT; Lin B; Hideshima T; Akiyama M; LeBlanc R; Catley L; Mitsiades N; Mitsiades C; Chauhan D; Munshi NC; Anderson KC
    Exp Hematol; 2002 Jul; 30(7):711-20. PubMed ID: 12135668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.
    Sodhi A; Montaner S; Patel V; Zohar M; Bais C; Mesri EA; Gutkind JS
    Cancer Res; 2000 Sep; 60(17):4873-80. PubMed ID: 10987301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
    Dankbar B; Padró T; Leo R; Feldmann B; Kropff M; Mesters RM; Serve H; Berdel WE; Kienast J
    Blood; 2000 Apr; 95(8):2630-6. PubMed ID: 10753844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.